Route 92 Medical has secured $50m in financing to support the next phase of its growth strategy.
New investor Sectoral Asset Management joined lead investor Novo Holdings, along with returning investors Norwest Venture Partners, US Venture Partners, The Vertical Group, and InnovaHealth Partners in the funding round.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The proceeds will support the next phase of growth through expediting worldwide commercial expansion, focusing on clinical evidence generation and investing in ongoing product development.
Route 92 Medical’s neurovascular portfolio includes the HiPoint Reperfusion System with the Monopoint approach, the first “super-bore” aspiration catheter featuring a mono-axial procedural approach and a 0.088in inner diameter cleared by the US Food and Drug Administration (FDA) for large vessel occlusions in acute ischemic stroke.
Route 92 Medical CEO and founder Tony Chou said: “We’ve seen rapid growth in the adoption of our products over the past year, attributable to the clinical performance of our Monopoint approach, and the growth and dedication of our commercial organisation.
“We’re on a mission to improve outcomes for patients suffering from acute ischemic stroke, and our rapidly growing sales are a testament to the differentiated, physician-preferred attributes of our neurovascular thrombectomy solutions.”
The company recently completed the SUMMIT MAX clinical trial, a multi-centre, prospective, randomised, and controlled endovascular stroke thrombectomy study involving 250 patients.
Trial results, demonstrating favourable safety and high first pass effect, supported FDA submission.
In September 2024, Route 92 Medical secured $50m as part of a Series F financing round aimed at supporting the global commercialisation of its FreeClimb and Tenzing devices.
